Quetiapine free base | CAS#111974-69-7 | 111974-72-2 | atypical antipsychotic

MedKoo Cat#: 319523 | Name: Quetiapine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Quetiapine, marketed as Seroquel, is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and along with an antidepressant to treat major depressive disorder. It is also sometimes used as a sleep aid because of its sedating effect but this use is not recommended. Quetiapine is a dopamine, serotonin, and adrenergic antagonist, and a potent antihistamine with clinically negligible anticholinergic properties. Quetiapine binds strongly to serotonin receptors; the drug acts as partial agonist at 5-HT1A receptors.

Chemical Structure

Quetiapine

CAS#111974-69-7 (free base)

Theoretical Analysis

MedKoo Cat#: 319523

Name: Quetiapine

CAS#: 111974-69-7 (free base)

Chemical Formula: C21H25N3O2S

Exact Mass: 383.1668

Molecular Weight: 383.51

Elemental Analysis: C, 65.77; H, 6.57; N, 10.96; O, 8.34; S, 8.36

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 350.00	2 Weeks
200mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

111974-72-2 (hemifumarate) 111974-69-7 (free base)

Synonym

ICI 204,636; ICI 204636; ICI-204636; ICI204636; quetiapine fumarate; Quetiapine; brand name: Seroquel.

IUPAC/Chemical Name

2-(2-(4-dibenzo[b,f][1,4]thiazepine- 11-yl- 1-piperazinyl)ethoxy)ethanol

InChi Key

URKOMYMAXPYINW-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2

SMILES Code

OCCOCCN1CCN(C2=NC3=CC=CC=C3SC4=CC=CC=C24)CC1

Appearance

TBD

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, ethanol, and water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# CAS# 111974-72-2 ( Quetiapine hemifumarate) CAS#111974-69-7 ( Quetiapine free base).

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Quetiapine is a dopamine, serotonin, and adrenergic antagonist, and a potent antihistamine with clinically negligible anticholinergic properties. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. It has antidepressant and anxiolytic effects.

In vitro activity:

Using PC12 cell cultures and the MTT assay for cell viability found that the atypical antipsychotics clozapine, quetiapine, and risperidone may exert a neuroprotective function after serum withdrawal through the modulation of SOD1 and p75NTR expression. They also found that 1) the atypical antipsychotics (clozapine, quetiapine, and risperidone) can protect PC12 cells from death after serum withdrawal and 2) these drugs up-regulated the SOD1 gene expression to more than 120% and also down-regulated p75NTR mRNA levels to less than 65% of their respective control values Reference: J Neurosci Res. 2002 Jul 15;69(2):278-83. https://pubmed.ncbi.nlm.nih.gov/12111809/

In vivo activity:

Quetiapine significantly reduced depressive-like behaviors induced by chronic mild stress in adult rats. MPO activity and IL-6 levels increased in the serum of animals submitted to CMS. Quetiapine significantly reduced MPO activity and IL-6 levels. These results corroborate other evidence, indicating that chronic stress is a relevant phenomenon in the etiology of depression and suggesting that quetiapine induces an antidepressant effect because it reduces oxidative and inflammatory mechanisms. Reference: Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 3. https://pubmed.ncbi.nlm.nih.gov/36735044/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	260.75
	Ethanol	100.0	260.75
	Water	0.1	0.26

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 383.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Le Daré B, Ferron PJ, Allard PM, Clément B, Morel I, Gicquel T. New insights into quetiapine metabolism using molecular networking. Sci Rep. 2020 Nov 16;10(1):19921. doi: 10.1038/s41598-020-77106-x. PMID: 33199804; PMCID: PMC7669884. 2. Bai O, Wei Z, Lu W, Bowen R, Keegan D, Li XM. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res. 2002 Jul 15;69(2):278-83. doi: 10.1002/jnr.10290. PMID: 12111809. 3. Grolli RE, Bertollo AG, Behenck JP, de Araujo Borba L, Plissari ME, Soares SJB, Manica A, da Silva Joaquim L, Petronilho F, Quevedo J, Bagatini MD, Réus GZ, Ignácio ZM. Quetiapine effect on depressive-like behaviors, oxidative balance, and inflammation in serum of rats submitted to chronic stress. Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 3. doi: 10.1007/s00210-023-02406-8. Epub ahead of print. PMID: 36735044. 4. Agrawal MB, Patel MM. Optimization and in vivo evaluation of quetiapine-loaded transdermal drug delivery system for the treatment of schizophrenia. Drug Dev Ind Pharm. 2020 Nov;46(11):1819-1831. doi: 10.1080/03639045.2020.1821051. Epub 2020 Sep 17. PMID: 32896163.

In vitro protocol:

In vivo protocol:

1. Grolli RE, Bertollo AG, Behenck JP, de Araujo Borba L, Plissari ME, Soares SJB, Manica A, da Silva Joaquim L, Petronilho F, Quevedo J, Bagatini MD, Réus GZ, Ignácio ZM. Quetiapine effect on depressive-like behaviors, oxidative balance, and inflammation in serum of rats submitted to chronic stress. Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 3. doi: 10.1007/s00210-023-02406-8. Epub ahead of print. PMID: 36735044. 2. Agrawal MB, Patel MM. Optimization and in vivo evaluation of quetiapine-loaded transdermal drug delivery system for the treatment of schizophrenia. Drug Dev Ind Pharm. 2020 Nov;46(11):1819-1831. doi: 10.1080/03639045.2020.1821051. Epub 2020 Sep 17. PMID: 32896163.

1: He Q, Zhu P, Liu X, Huo C. Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis. Schizophr Res. 2024 Aug 6;271:371-379. doi: 10.1016/j.schres.2024.07.028. Epub ahead of print. PMID: 39111258. 2: Nash RP, Wang L, Gaynes BN, Flythe JE. Atypical Antipsychotics and the Risk of Sudden Cardiac Death among Individuals Receiving Maintenance Hemodialysis. Gen Hosp Psychiatry. 2023 Nov-Dec;85:148-154. doi: 10.1016/j.genhosppsych.2023.10.016. Epub 2023 Oct 24. PMID: 39108558; PMCID: PMC11299855. 3: Kikuchi Y, Kurosawa M, Sakata M, Takahashi Y, Yamamoto K, Tomita H, Yoshio T, Yasui-Furukori N. Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals. Br J Psychiatry. 2024 Aug 6:1-7. doi: 10.1192/bjp.2024.113. Epub ahead of print. PMID: 39104017. 4: Mitra S, Sareen A, Amazan R, Rothman S, Pakniyat-Jahromi S, Gunturu S. "My sister wants to kill me": A case report and systematic review of literature of co-occurring multiple sclerosis and psychosis. Indian J Psychiatry. 2024 Mar;66(3):247-255. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_103_22. Epub 2024 Mar 18. PMID: 39100118; PMCID: PMC11293287. 5: Inoue F, Okazaki Y, Huh K, Ichiba T, Chiba T, Namera A. Pharmacobezoar Associated Prolonged Clinical Course in a Patient with Immediate Release Quetiapine Overdose. J Med Toxicol. 2024 Aug 2. doi: 10.1007/s13181-024-01029-6. Epub ahead of print. PMID: 39093496. 6: Kim SH, Jung DU, Kim DH, Lee JS, Lee KU, Won S, Lee BJ, Kim SG, Roh S, Park JI, Kim M, Jung SW, Oh HS, Jung HY, Kim SH, Chee HS, Paik JW, Lee KY, Kim SI, Lee SH, Cheon EJ, Kim HG, Lee HJ, Chung IW, Choi J, Kim MH, Cho SJ, Youn H, Chang JG, Song HR, Kim E, Kim WH, Kim CE, Park DH, Lee BO, Lee J, Lee SY, Kang N, Jung HY. Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial. Psychiatry Investig. 2024 Jul;21(7):762-771. doi: 10.30773/pi.2024.0052. Epub 2024 Jul 24. PMID: 39089702; PMCID: PMC11298266. 7: Chan L, Corso G. Pharmacological and non-pharmacological prevention and management of delirium in critically ill and palliative patients in the inpatient setting: a review. Front Med (Lausanne). 2024 Jul 17;11:1403842. doi: 10.3389/fmed.2024.1403842. PMID: 39086947; PMCID: PMC11288933. 8: Lü W, Liu F, Zhang Y, He X, Hu Y, Xu H, Yang X, Li J, Kuang W. Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis. BMJ Ment Health. 2024 Jul 30;27(1):e301019. doi: 10.1136/bmjment-2024-301019. PMID: 39079887; PMCID: PMC11293415. 9: Yang R, Wan JL, Pi CQ, Wang TH, Zhu XQ, Zhou SJ. Increased antipsychotic drug concentration in hospitalized patients with mental disorders following COVID-19 infection: a call for attention. Front Psychiatry. 2024 Jul 15;15:1421370. doi: 10.3389/fpsyt.2024.1421370. PMID: 39077630; PMCID: PMC11284031. 10: Pihlaja T, Oksanen T, Vinkvist N, Sikanen T. Many human pharmaceuticals are weak inhibitors of the cytochrome P450 system in rainbow trout (Oncorhynchus mykiss) liver S9 fractions. Front Toxicol. 2024 Jul 15;6:1406942. doi: 10.3389/ftox.2024.1406942. PMID: 39077557; PMCID: PMC11284600. 11: Yousof SM, Shehata SA, Ismail EA, Abd El-Moneam SM, Mansour BSA, Farag MA, Elshamy AI, El-Nasser G El Gendy A, Serag A, Abd El-Fadeal NM, Abdel-Karim RI, Mostafa MM, El-Sheikh DH, Zayed MA. Acaciasaligna extract alleviates quetiapine-induced sexual toxicity in male albino rats: Insights from UPLC-MS/MS metabolite profiling, structural and PI3K/NF-κB pathway assessments. Heliyon. 2024 Jul 3;10(13):e33993. doi: 10.1016/j.heliyon.2024.e33993. PMID: 39071580; PMCID: PMC11280294. 12: Park YM. Alteration of Functional Connectivity before and after Electroconvulsive Therapy in a Single Patient with Depression and Catatonia. Clin Psychopharmacol Neurosci. 2024 Aug 31;22(3):537-540. doi: 10.9758/cpn.23.1096. Epub 2023 Jul 12. PMID: 39069694; PMCID: PMC11289609. 13: Su CS, Kao CL. Stevens-Johnson syndrome-toxic epidermal necrolysis overlap in a patient taking quetiapine and famotidine: a case report. J Med Case Rep. 2024 Jul 28;18(1):344. doi: 10.1186/s13256-024-04629-6. PMID: 39068499; PMCID: PMC11283697. 14: Vaidya R, Hashmi N, Kakshapati S, Chang W, Beachy J. Non epileptiform abnormal neurologic signs in newborns following in-utero psychotropic medication exposure. J Neonatal Perinatal Med. 2024 Jul 23. doi: 10.3233/NPM-230165. Epub ahead of print. PMID: 39058453. 15: Witt K, Levin J, van Eimeren T, Hasan A, Ebersbach G; German Parkinson’s Guideline Group. Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology. J Neurol. 2024 Jul 24. doi: 10.1007/s00415-024-12576-x. Epub ahead of print. PMID: 39046524. 16: Colijn MA. Quetiapine, Clozapine, and Pimavanserin Treatment Response in Monogenic Parkinson's Disease Psychosis: A Systematic Review. J Neuropsychiatry Clin Neurosci. 2024 Jul 22:0. doi: 10.1176/appi.neuropsych.20230231. Epub ahead of print. PMID: 39034670. 17: Chiang CY, Lo SC, Beckstead JW, Yang CY. Associations between constipation risk and lifestyle, medication use, and affective symptoms in patients with schizophrenia: a multicenter cross-sectional study. Soc Psychiatry Psychiatr Epidemiol. 2024 Jul 20. doi: 10.1007/s00127-024-02729-8. Epub ahead of print. Erratum in: Soc Psychiatry Psychiatr Epidemiol. 2024 Aug 6. doi: 10.1007/s00127-024-02743-w. PMID: 39033249. 18: Gonzalo-de Miguel A, Abascal-Peiró S, Cegla-Schvartzman FB, Martínez-Alés G, Baca-García E. Antipsychotic use in a large community sample of patients with delusional disorder. Schizophr Res. 2024 Jul 19;271:194-199. doi: 10.1016/j.schres.2024.07.040. Epub ahead of print. PMID: 39032432. 19: Kulkarni J, De Chellis A, Gilbert H, Gavrilidis E, Mu E, Karimi L, Li Q. Clozapine Safety in Pregnancy: A Clinical Study. Schizophr Bull. 2024 Jul 20:sbae132. doi: 10.1093/schbul/sbae132. Epub ahead of print. PMID: 39031964. 20: Zhao M, Ma J, Wu Y, Zhang Y, Wang L, Song H, Sun X. Depressive and anxiety symptoms among schizophrenia patients. J Affect Disord. 2024 Jul 17;362:749-754. doi: 10.1016/j.jad.2024.07.130. Epub ahead of print. PMID: 39029687.